NCT05516875 is a Phase 2 clinical trial of JM-010 in Dyskinesias, sponsored by Contera Pharma A/S.

Who is sponsoring NCT05516875?

NCT05516875 is sponsored by Contera Pharma A/S.

What drugs are being tested in NCT05516875?

Interventions in NCT05516875: JM-010.

What condition does NCT05516875 study?

NCT05516875 studies Dyskinesias.

Is NCT05516875 still recruiting?

NCT05516875 is currently terminated. Last updated 15 October 2024.

Last reviewed 2024-10-15 · How we verify

NCT05516875

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open-Label Extension Study of ASTORIA

Terminated Phase 2 Last updated 15 October 2024

What this trial tests

Phase 2 trial testing JM-010 in Dyskinesias in 6 participants. Terminated before completion.

Timeline

19 January 2024

Primary endpoint
22 May 2024

27 June 2024

Quick facts

Lead sponsor	Contera Pharma A/S
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	19 January 2024
Primary completion	22 May 2024
Estimated completion	27 June 2024
Sites	2 locations across Italy, Spain

Drugs / interventions tested

JM-010 — full drug profile →

Conditions studied

Dyskinesias — all drugs for Dyskinesias →

Sponsor

Contera Pharma A/S — full company profile →

Who can join

Eligibility, any sex, with Dyskinesias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This current open-label extension (OLE) study (JM-010CS-OL) will explore the safety and tolerability of long-term administration of JM-010 of patients who completed 12-week treatment of Phase 2 (JM-010CS03) study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nanotherapeutic Interventions for Parkinson's Disease: Modulating Pathogenic Mechanisms and Overcoming Therapeutic Obstacles.
Yin X, Wang C, Lin W, Huang S, et al · · 2026 · PMID 41907367 · DOI 10.2147/ijn.s570452

Verify or expand the search:

Other recruiting trials for Dyskinesias

Currently open trials in the same condition.

NCT07023224 — Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26) · recruiting
NCT06585605 — A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia · recruiting
NCT05317390 — Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05516875 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Contera Pharma A/S
Last refreshed: 15 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05516875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing